Combining several therapies to build a rehabilitation treatment plan for neurological conditions is nothing new. However, combining a variety of technologies into a treatment plan to produce functional outcomes is an emerging theme among innovative rehabilitation professionals. The roots of combining the rehabilitation with electrical stimulation to improve motor re-learning come from the pioneering work by Dr. Randolph Nudo and Dr. Alvaro Pascual-Leone in 1990es.
Recently, this approach was applied by combining the robotic therapy with electrical or magnetic stimulation by a team of researchers lead by Dr. Lumy Sawaki at the University of Kentucky in Lexington. This new neural rehabilitation technique capitalizes on “neuroplasticity,” which refers to the brain’s ability to reorganize itself by forming new neural connections to compensate for injury and disease. Dr. Lumy Sawaki, MD, PhD, an Associate Professor in the Department of Physical Medicine and Rehabilitation at the University of Kentucky, has been exploring how combining technologies in the rehabilitation setting may help her patients regain functional movements. This new therapy is based on previous work she had done involving CIMT, constraint-induced movement therapy. Dr. Sawaki was the lead author on a CIMT study published in the journal Neurorehabilitation and Neural Repair. In this study, each of the 30 participants was evaluated using transcranial magnetic stimulation (TMS), a non-invasive method to excite neurons in the primary motor cortex. In the CIMT therapy study, Dr. Sawaki and collaborators used TMS to map the area of the brain that controls a particular muscle and compared this map to previous patterns of activity. As the patient’s ability to perform a certain movement improves, these brain maps confirm the reorganization of the associated area of the brain. Focusing on hand motor function of sub-acute stroke survivors, they observed changes within the functional activity of the brain for those who used CIMT.
Building on this previous work, Dr. Sawaki and her research team are evaluating the combined approach to stimulate the brain with two painless and non-invasive methods: the magnetic stimulation with TMS and the electrical stimulation with transcranial direct current stimulation (tDCS), to develop a new neural rehabilitation therapy for chronic survivors of neurological trauma from stroke, brain and spinal cord injuries. In this new therapy, the TMS and tDCS is applied along with robotic movement therapy, such as body weight supported treadmill training. Dr. Sawaki is using TMS and tDCS to stimulate the area inside the motor cortex that controls movement of a targeted muscle. By applying multiple stimuli and monitoring the muscle response combined with robotic therapy, the investigators are attempting to determine if this combination will result in higher functional benefit.
Conclusive evidence is still lacking but it brings the promise of combined neural rehabilitation therapies paving a new path for how we approach complex neurological conditions in the rehabilitation setting. Click here to read more about Dr. Lumy Sawaki’s research and new neurorehabilitation therapy.


Central-nervous-system based neuromotor prosthesis (NMP) holds a great deal of promise for complete spinal cord injury (SCI) yet is still far from the clinical use. Cortical-level NMP uses direct cortical recording and requires craniotomy for implanting a microelectrode array in the motor cortical area of an injured person. First successful human trial of the cortical NMP in a quadriplegic person, the BrainGate, was done by Dr. Donoghue and colleagues
An international research team from Japan, Germany, and United States
A few months ago,
In order to use a medical device in the US, a device manufacturer has to get an approval from FDA. Invasive devices, such as neural implants, are classified as Class III and can be approved in one of two ways: 1) a comprehensive “de novo” Premarket Approval (PMA) or 2) a streamlined 510(k) clearance, also called a Premarket Notification (PMN), when the device is “substantially equivalent” to an existing approved device. The complete device development and approval process takes 4-10 years and costs $5-300 million depending on the complexity of the device and FDA approval process. Approximately 40 PMAs and 3,000 510(k) clearances are approved each year by the FDA.
Upper (e.g. bronchial) airways become constricted in people with asthma or chronic obstructive pulmonary disease. The bronchial smooth muscle contraction is mediated by the parasympathetic nervous system, while the relaxation is mediated by the sympathetic nervous system. The periaqueductal gray matter of the midbrain (PAG) and subthalamic nucleus (STN) are involved in maintaining the bronchial relaxation. The electrical stimulation of the PAG is approved for chronic pain and electrical stimulation of the STN – for movement disorders (Parkinson disease and dystonia). A 
The ICNPD-2011 conference took place on November 25-26 2011 on the campus of University of New South Wales in Sydney, Australia. As a co-chair of the conference, it is my great pleasure to report on its results. The conference drew 70 participants, and included 25 speakers from 9 countries (Australia, China, Denmark, Germany, Korea, Singapore, Taiwan, UK, and USA). Owing to a multi-disciplinary nature of the neuroprosthetic research, the talks were given by scientists, engineers, neurosurgeons, and rehabilitation physicians and covered a wide range of topics, such as new materials, surgical approaches, uses of electrochemical and neurophysiological recordings, circuit design, and signal processing algorithms. During the poster session, 16 posters were presented, including 8 student posters evaluated by the members of Scientific Committee. The Best Student Poster award, the iPad2, was given to Dr. Spencer Chen, a post-doctoral fellow at the University of New South Wales; and the runner-up award was given to Dr. Chandan Reddy, a post-doctoral fellow at the University of Iowa. Following the conference, a series of online discussions were held with the speakers to come up with a list of Grand Innovation Challenges in Neural Prosthetics:
The neuroscientists at UC Berkeley
During stimulation, the applied electrical charge induces similar flows of multiple extracellular cations (K+,Na+ and Ca2+) in the electrode vicinity. This is rather counter-productive as these cations play varying roles in the initiation and propagation of action potentials. As a result, a significant percentage of applied electric charge is being wasted. Now, scientists at MIT and Harvard Medical School have
About 3 -4% of the general population has or will develop a cerebral aneurysm, with most are without any symptoms. Aneurysm is an enlarged area of a blood vessel that usually develops at a branching point of artery and is caused by constant pressure from blood flow. It often grows gradually and becomes weaker as it stretches. Rupture of a cerebral aneurysm causes bleeding into the brain, often leading to a stroke. Endovascular embolization using micro-coils has emerged as a successful preventive treatment for aneurysms. The micro-coils are made from platinum wire (thickness 20–120 μm) wound at diameters of 200–500 μm for length up to 50 cm. Once the coil is inserted through the artery into the aneurysm, it forms a randomly tangled globe that promotes clotting of blood, thus preventing further inflow of blood and pressure rise. In about half of implanted patients,
As documented in other posts on this blog, mutliple neural prosthetic devices are currently being developed by startup companies throughout the US, Europe, and Asia. Practically all of these startups are pursuing the well-established R&D strategy of building a device to treat a specific neurological disorder and going through a lengthy process toward eventual FDA approval and reimbursement by private and government-run health insurance companies. In following with this R&D strategy, the resulting device is usually fully implanted and contains only the circuitry needed for its primary function to treat a specific disorder. The device is designed for autonomous operation without user accessibility, and any device’s software tuning/upgrade requires a physician and specialized clinical equipment. These features are aimed at limiting the manufacturer’s and surgeon’s liabilities.
As the number of people with Alzheimer’s disease (AD) is rising with aging population, there is an increasing urgency in developing an effective approach to slow its progression. Despite the efforts by pharmaceutical companies, currently approved drugs provide only modest effects and are often difficult to target to the brain without avoiding the systemic side effects. A possibility of using electrical stimulation for combating the disease has not been considered until a serendipitous discovery
The quest for highly functional neuroprosthetics in activities of daily living has implicitly assumed that the neural interface would include both motor and sensory (i.e. tactile and proprioceptive) functionalities. It is likely that for reaching and grasping tasks, the dynamic sensorimotor programs will need to be developed to enable dexterous control. Interestingly, the neural decoding, stimulation, and hardware principles for sensorimotor interfaces are often developed in isolation in motor-only or sensory-only studies. In this week’s issue of the journal Nature, a